Back

Dapagliflozin but not empagliflozin prevents atrial fibrillation in an experimental whole-heart model

26 August 2022 (17:10 - 17:30)
Organised by:
Congress Presentation Part of: Insights into arrhythmia mechanisms Cellular Electrophysiology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Gerrit Frommeyer

University Hospital of Munster, Munster (Germany)

2 More presentations in this session

Presentation thumbnail
State-of-the-art lecture in arrhythmia mechanisms.
Professor U. Schotten (Maastricht, NL)
Slides Video
Presentation thumbnail
Dapagliflozin exhibits class I antiarrhythmic effects which suppress action potential formation in human atrial cardiomyocytes
Miss A. Paasche (Heidelberg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Insights into arrhythmia mechanisms
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 17:10 CET
You may be interested in
thumbnail
Congress Presentation
The effect of SGLT2 inhibitor on clinical outcomes in patients with type 2 diabetes and atrial fibrillation
thumbnail
Congress Presentation
The impact of dapagliflozin on left atrial functions in non-diabetic atrial fibrillation patients in the early post-cryoablation period
thumbnail
Congress Presentation
Characterization of atrial cardiomyopathy subtypes - A cellular electrophysiological comparison and evaluation of appropriate treatment options

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources